Daily Bulletin

Men's Weekly

.

PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (metastatic Triple-Negative Breast Cancer)...

Read more: PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

Business News

Digital Marketing Agency in Sydney: Empowering Businesses with Smart Online Growth Strategies

Sydney’s business scene is fast-paced, diverse, and incredibly competitive. In such a dynamic environment, having a strong online presence is no longer optional — it’s essential. A digital marketing...

Daily Bulletin - avatar Daily Bulletin

Why Your Business Might Already Be a Cybercrime Target Without Knowing It

Cybercrime isn’t just something that happens to banks or large technology companies. It can happen to any business, even those that seem too small to matter. When a hacker sees an easy target, they ta...

Daily Bulletin - avatar Daily Bulletin

Car Rental as a Practical and Flexible Solution for Travel or Work

The contemporary, hectic way of life is one of ease and adaptability while commuting and working. Regardless of whether one moves around by road, commuting between towns for conferences, or taking a f...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business